Haemonetics (HAE) Reports Q4 2026 Earnings Results and Insights

Haemonetics (HAE) announced its Q4 2026 earnings, reporting a revenue increase of 10% year-over-year to $250 million. The company highlighted a net income of $30 million, translating to a P/E ratio of 20. This growth indicates strong demand in the healthcare sector. Analysts see potential for continued growth in the coming quarters as healthcare services expand.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.